Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas

(2017) Cindy Neuzillet et al.   PHARMACOLOGY & THERAPEUTICS

A phase II study of axitinib in advanced neuroendocrine tumors

(2016) J R Strosberg et al.   ENDOCRINE-RELATED CANCER

Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis

(2016) Omar Abdel-Rahman et al.   Future Oncology

A phase II study of nintedanib in patients with relapsed small cell lung cancer

(2016) Ji-Youn Han et al.   LUNG CANCER

Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling

(2016) Elizabeth Allen et al.   Cell Reports

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

(2015) E. Grande et al.   ANNALS OF ONCOLOGY

Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model

(2015) R. Bill et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

(2015) M. Schlumberger et al.   CLINICAL CANCER RESEARCH

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study

(2015) Alexandria T Phan et al.   LANCET ONCOLOGY

Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for ‘Off-Target' Effects Not Mediated by c-Met Inhibition

(2015) Clemens Reuther et al.   NEUROENDOCRINOLOGY

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cabozantinib: A Review of Its Use in Patients with Medullary Thyroid Cancer

(2014) Sheridan M. Hoy   DRUGS

A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H

(2014) Keith C. Bible et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models

(2014) Haifu Li et al.   Translational Oncology

Overview of fundamental study of pazopanib in cancer

(2014) Hong-Lin Zhao et al.   Thoracic Cancer

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

(2013) H K Ahn et al.   BRITISH JOURNAL OF CANCER

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes

(2013) D J Pinato et al.   BRITISH JOURNAL OF CANCER

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

(2013) Jennifer A. Chan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies

(2013) Federica Barbieri et al.   DRUG DISCOVERY TODAY

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

(2013) Daniel Castellano et al.   EUROPEAN JOURNAL OF CANCER

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

(2013) B. Kutluk Cenik et al.   MOLECULAR CANCER THERAPEUTICS

Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients

(2012) Cen Xie et al.   BRITISH JOURNAL OF PHARMACOLOGY

EMT and Dissemination Precede Pancreatic Tumor Formation

(2012) Andrew D. Rhim et al.   CELL

Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

(2012) Jennifer A. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway

(2012) Seiichi Hosaka et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors

(2012) Judith A. Gilbert et al.   PANCREAS

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography

(2011) Xiao-Dong Zhu et al.   BMC CANCER

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors

(2011) Patricia Kuiper   WORLD JOURNAL OF GASTROENTEROLOGY

Pazopanib in Renal Cell Carcinoma

(2010) J. E. Ward et al.   CLINICAL CANCER RESEARCH

Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis

(2010) B. Gril et al.   CLINICAL CANCER RESEARCH

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo

(2010) J. Paesler et al.   CLINICAL CANCER RESEARCH

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

(2010) Kae Hashimoto et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)

(2009) Gerald J. Roth et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines

(2009) K A Olaussen et al.   ONCOGENE

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors

(2008) A. Couvelard et al.   CLINICAL CANCER RESEARCH

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiogenesis and Tumor Progression in Neuroendocrine Digestive Tumors

(2008) Gilles Poncet et al.   JOURNAL OF SURGICAL RESEARCH

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS